|
| | Thymopentin Basic information |
| | Thymopentin Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | DMF: 30 mg/ml; DMSO: 25 mg/ml; Ethanol: 1 mg/ml; PBS (pH 7.2): 10 mg/ml | | form | Powder | | pka | 3.07±0.10(Predicted) | | color | White | | CAS DataBase Reference | 69558-55-0(CAS DataBase Reference) |
| WGK Germany | 3 | | HS Code | 3504009000 |
| | Thymopentin Usage And Synthesis |
| Description | Thymopentin is a kind of peptide. Peptides and polypeptides play a critical role in the immune system and are therefore predestined as a source for new approaches in immunotherapy. Thymopentin is capable of modulating the immune response. It is a fragment of the thymopoietins (TMPOs) which is a family of nuclear protein. Studies have shown that Thymopentin is capable of affecting the function of T cells and monocytes monitored by increased cGMP level and the triggering of cellular signaling. It is also capable of improve an imbalanced immune system. As an immunomodulating agent, it is clinically used in the treatment of autoimmune diseases such as atopic dermatitis, chronic lymphocytic leukemia, Sezary’s syndrome, rheumatoid arthritis and decreased immune competency. Recent study has also shown that its immuno-modulating effect can also help fight against the infection of mycobacterium tuberculosis.
| | Originator | Janssen (Belgium) | | Uses | Thymopentin Acetate (TP-5) is a synthetic immunomodulating pentapeptide. | | Uses | immunoregulator | | Definition | ChEBI: Thymopentin is an oligopeptide. | | Brand name | SINTOMODULINA; TIMUNOX | | Clinical Use | Thymopentin is a synthetic, immunomodulating pentapeptide, representing the
active fragment of the thymus hormone, thymopoietin. Thymopentin induces
phenotypic differentiation and maturation of T-cells. It appears of value in the
treatment of primary immune deficiency, rheumatoid arthritis, atopic dermatitis,
sarcoidosis and a variety of other diseases with manifestations of disturbed
immune balance. | | References | Zhang, Yan, et al. "Novel thymopentin release systems prepared from bioresorbable PLA–PEG–PLA hydrogels." International journal of pharmaceutics 386.1 (2010): 15-22.
Gonser, S., E. Weber, and G. Folkers. "Peptides and polypeptides as modulators of the immune response: thymopentin—an example with unknown mode of action." Pharmaceutica Acta Helvetiae 73.6 (1999): 265-273.
Wang, Ying, et al. "Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity." Biomaterials 35.9 (2014): 3102-3109.
|
| | Thymopentin Preparation Products And Raw materials |
|
